Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
March 20, 2023
What’s new in breast cancer research? SABCS 2022 delivers plenty
Studies highlight research on treatment toxicity, disparities in insurance, gaps in metastatic care, new therapies and more
Fred Hutch/UW/Seattle Children’s Cancer Consortium breast cancer researchers receive grants
Breast Cancer Research Foundation supports projects including new imaging tracer, better risk prediction for luminal B subtypes, anti-inflammatory vaccine and more
What’s new in breast cancer research? SABCS20 goes virtual
Hutch scientists share findings on treatment, imaging, CAR T therapy, COVID-19’s impact on cancer patients and more
Patients navigate cancer during COVID-19 pandemic
Scary waiting rooms, delayed scans and ‘virtual’ care: patients and providers try to dodge the collateral damage of coronavirus
Trio of studies to evaluate metastatic breast cancer care
Hutch researcher awarded grants to study the use of biopsy to drive therapy choices and test new type of PET scan to stage lobular
What's new in breast cancer research: #SABCS19 edition
Fred Hutch researchers share long-term follow-up data on WHI hormone study, anti-hormone side-effect strategies and more at San Antonio meeting
Cancer patients find clinical trials, hope and help
#NWMetsConf connects metastatic breast cancer patients with trials, treatments, tools and each other
Metastatic breast cancer patients gather in Seattle to talk research, cures
300 patients, advocates and researchers talk science, health disparities and filling in crucial data gaps at 'mets' conference
PET scans confirm effectiveness of estrogen-blocking therapy
SCCA study findings have implications for personalized breast cancer treatment and drug development
Potentially 'powerful tool' for noninvasive cancer treatment assessment
Linden and colleagues find PET scans can provide accurate, early assessment of response to breast-cancer therapy